Celyad's lead candidate, NKR-2, is a T-Cell engineered to express the human NK receptor, NKG2D, which is an activating receptor
that triggers cell killing through the binding of NKG2D to any of eight naturally occurring ligands that are known to be overexpressed on more than 80% of tumours.
Sanofi and Innate Pharma entered a research collaboration and licensing agreement to apply Innate Pharma's new proprietary technology to the development of innovative bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells through the activating receptor NKp46.
By building on our knowledge of the activating receptor NKp46, we have generated a technology to specifically induce tumor killing by NK cells.
Innate Pharma and Sanofi has signed a research partnership and licensing deal to apply Innate Pharma's new proprietary technology to the development of innovative bispecific antibody formats engaging natural killer or NK cells to kill tumor cells via activating receptor
The goal is to develop the next generation of act through t cell engineering both by forced expression of migratory and activating receptors
and simultaneous deletion of immune suppressive molecules by gene editing.
The triggering receptors expressed on myeloid cells (TREM) are a family of activating receptors
that participate in diverse cell processes, including inflammation, bone homeostasis, neurological development and coagulation.
Tony Lam at the Toronto General Research Institute and the University of Toronto discovered that activating receptors
of the cholecystokinin (CCK) peptide hormone in the gut rapidly and potently lowers blood glucose levels by triggering a signal to the brain and then to the liver to lower glucose or sugar production.
They found that versican strongly enhances LLC metastatic growth by activating receptors
that lead to production of cytokines - signaling proteins that regulate the immune system.